Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.

Literature DB >> 28733323

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.

Joseph M Connors¹, Stephen M Ansell², Michelle Fanale³, Steven I Park⁴, Anas Younes⁵.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2017 PMID： 28733323 PMCID： PMC5766843 DOI： 10.1182/blood-2017-05-784678

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

11 in total

1. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

Authors: A S Gerrie; M M Power; J D Shepherd; K J Savage; L H Sehn; J M Connors
Journal: Ann Oncol Date: 2014-08-22 Impact factor: 32.976

2. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Authors: Francesco Merli; Stefano Luminari; Paolo G Gobbi; Nicola Cascavilla; Caterina Mammi; Fiorella Ilariucci; Caterina Stelitano; Maurizio Musso; Luca Baldini; Sara Galimberti; Francesco Angrilli; Giuseppe Polimeno; Potito Rosario Scalzulli; Angela Ferrari; Luigi Marcheselli; Massimo Federico
Journal: J Clin Oncol Date: 2015-12-28 Impact factor: 44.544

3. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors: Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544

Review 4. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma.

Authors: Joseph M Connors
Journal: Blood Date: 2015-01-09 Impact factor: 22.113

5. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Authors: Anas Younes; Joseph M Connors; Steven I Park; Michelle Fanale; Megan M O'Meara; Naomi N Hunder; Dirk Huebner; Stephen M Ansell
Journal: Lancet Oncol Date: 2013-11-15 Impact factor: 41.316

6. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Authors: Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg
Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544

7. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.

Authors: Greg Hapgood; Yvonne Zheng; Laurie H Sehn; Diego Villa; Richard Klasa; Alina S Gerrie; Tamara Shenkier; David W Scott; Randy D Gascoyne; Graham W Slack; Christina Parsons; James Morris; Tom Pickles; Joseph M Connors; Kerry J Savage
Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544

8. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

Authors: Patrice Carde; Matthias Karrasch; Catherine Fortpied; Pauline Brice; Hussein Khaled; Olivier Casasnovas; Denis Caillot; Isabelle Gaillard; Serge Bologna; Christophe Ferme; Pieternella Johanna Lugtenburg; Frank Morschhauser; Igor Aurer; Bertrand Coiffier; Ralph Meyer; Matthew Seftel; Max Wolf; Bengt Glimelius; Anna Sureda; Nicolas Mounier
Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544

9. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

Authors: Leo I Gordon; Fangxin Hong; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Patrick J Stiff; Bruce D Cheson; Mary Gospodarowicz; Ranjana Advani; Brad S Kahl; Jonathan W Friedberg; Kristie A Blum; Thomas M Habermann; Joseph M Tuscano; Richard T Hoppe; Sandra J Horning
Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544

10. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors: John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal: N Engl J Med Date: 2015-04-23 Impact factor: 91.245

9 in total

Review 1. Update on the role of brentuximab vedotin in classical Hodgkin lymphoma.

Authors: Sarah Tomassetti; Alex F Herrera
Journal: Ther Adv Hematol Date: 2018-07-12

2. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors: Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245

Review 3. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors: Helen Ma; Ahmed Sawas
Journal: Curr Hematol Malig Rep Date: 2018-12 Impact factor: 3.952

Review 4. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

Authors: Yucai Wang; Grzegorz S Nowakowski; Michael L Wang; Stephen M Ansell
Journal: J Hematol Oncol Date: 2018-04-23 Impact factor: 17.388

Review 5. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.

Authors: Shinichi Makita; Dai Maruyama; Kensei Tobinai
Journal: Onco Targets Ther Date: 2020-06-23 Impact factor: 4.147

Review 6. Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group.

Authors: Reena Nair; Abhishek Kakroo; Ajay Bapna; Ajay Gogia; Amish Vora; Anand Pathak; Anu Korula; Anupam Chakrapani; Dinesh Doval; Gaurav Prakash; Ghanashyam Biswas; Hari Menon; Maitreyee Bhattacharya; Mammen Chandy; Mayur Parihar; M Vamshi Krishna; Neeraj Arora; Nikhil Gadhyalpatil; Pankaj Malhotra; Prasad Narayanan; Rekha Nair; Rimpa Basu; Sandip Shah; Saurabh Bhave; Shailesh Bondarde; Shilpa Bhartiya; Soniya Nityanand; Sumeet Gujral; T V S Tilak; Vivek Radhakrishnan
Journal: Indian J Hematol Blood Transfus Date: 2018-08-03 Impact factor: 0.900